Skip to content

News

Q&A with OCRFA Grantee Kris Wood, PhD

Q&A with OCRFA Grantee Kris Wood, PhD

Q&A with Kris Wood, PhD Duke University 2015 Liz Tilberis Award   OCRFA: Tell me about yourself. Kris Wood: I grew up in Georgetown, KY, a rural town in the … Continued

Ovarian Cancer National Alliance honored for advocacy work

Ovarian Cancer National Alliance honored for advocacy work

FOR IMMEDIATE RELEASE June 15, 2015 Ovarian Cancer National Alliance honored for advocacy work OCNA called “leading advocacy organization for women impacted by ovarian cancer” WASHINGTON, DC — On Saturday, … Continued

Teaming Up Against Ovarian Cancer

Teaming Up Against Ovarian Cancer

(9/11/15) By Alan D. D’Andrea, MD, Dana-Farber Cancer Institute and Harvard Medical School, and Elizabeth M. Swisher, MD, University of Washington September is Ovarian Cancer Awareness Month, when we scientists … Continued

OCRF Research Finds Combination Immunotherapy Promising

OCRF Research Finds Combination Immunotherapy Promising

(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By … Continued

New York Times Letter to the Editor

New York Times Letter to the Editor

On August 3, 2015 the New York Times published an article about the use of IP chemotherapy in the treatment of ovarian cancer. Our CEO, Calaneet Balas joined with Ovarian Cancer Research Fund CEO, Audra Moran, to write a response to the New York Times. Click the plus sign to see their Letter to the Editor.

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.